Runx1缺失可防止心肌梗死后不良心脏重构
该研究在心肌梗死(MI)小鼠模型中探究Runx1转录因子的功能,通过他莫昔芬诱导的心肌细胞特异性Runx1缺陷小鼠进行冠脉结扎。结果显示Runx1缺失小鼠可抵抗MI后不良心脏重构,维持室壁厚度和收缩功能,其机制涉及PKA磷酸化受磷蛋白增强SERCA活性。
要点
- Runx1缺失可保护MI后不良心脏重构并维持收缩功能。
- Runx1缺失小鼠无离心性肥厚,心肌细胞钙处理明显改善。
- 机制为PKA磷酸化受磷蛋白解除SERCA抑制,增加SR钙释放。
核心结论
- Runx1缺失可防止MI后不良心脏重构并维持收缩功能,提示Runx1是具有转化潜力的新治疗靶点。
研究设计与样本
- 研究构建了他莫昔芬诱导的心肌细胞特异性Runx1缺陷小鼠,并采用冠状动脉结扎术诱导MI。
- 在整体心脏、心肌细胞和分子水平评估心脏重构与收缩功能。
主要发现
- Runx1缺陷小鼠在MI后受到保护,维持了心室壁厚度和收缩功能。
- Runx1缺陷小鼠缺乏离心性肥厚,心肌细胞钙处理明显改善。
- 机制上,Runx1缺陷通过增加蛋白激酶A对受磷蛋白的磷酸化、解除肌浆/内质网Ca2+-ATPase抑制来实现上述效应。
- Runx1缺陷小鼠中增强的SERCA活性增加了肌浆网钙含量和肌浆网介导的钙释放,从而在MI后保持心肌细胞收缩。
临床怎么用
- Runx1可作为MI后不良心脏重构的潜在治疗靶点,但尚需进一步转化研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Myocardial infarction (MI) is a leading cause of heart failure and death worldwide. Preservation of contractile function and protection against adverse changes in ventricular architecture (cardiac remodeling) are key factors to limiting progression of this condition to heart failure. Consequently, new therapeutic targets are urgently required to achieve this aim. Expression of the Runx1 transcription factor is increased in adult cardiomyocytes after MI; however, the functional role of Runx1 in the heart is unknown. METHODS: To address this question, we have generated a novel tamoxifen-inducible cardiomyocyte-specific Runx1-deficient mouse. Mice were subjected to MI by means of coronary artery ligation. Cardiac remodeling and contractile function were assessed extensively at the whole-heart, cardiomyocyte, and molecular levels. RESULTS: Runx1-deficient mice were protected against adverse cardiac remodeling after MI, maintaining ventricular wall thickness and contractile function. Furthermore, these mice lacked eccentric hypertrophy, and their cardiomyocytes exhibited markedly improved calcium handling. At the mechanistic level, these effects were achieved through increased phosphorylation of phospholamban by protein kinase A and relief of sarco/endoplasmic reticulum Ca2+-ATPase inhibition. Enhanced sarco/endoplasmic reticulum Ca2+-ATPase activity in Runx1-deficient mice increased sarcoplasmic reticulum calcium content and sarcoplasmic reticulum-mediated calcium release, preserving cardiomyocyte contraction after MI. CONCLUSIONS: Our data identified Runx1 as a novel therapeutic target with translational potential to counteract the effects of adverse cardiac remodeling, thereby improving survival and quality of life among patients with MI.
引用
- McCarroll CS, He W, Foote K, et al. Runx1 Deficiency Protects Against Adverse Cardiac Remodeling After Myocardial Infarction. Circulation. 2017. PMID: 29030345. doi:10.1161/CIRCULATIONAHA.117.028911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。